Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19799048 | 1.00 | KDM2B (0.36) | KDM2BDPP4MEN1KMT2AALDH1A1 | |
| SCHEMBL19799047 | 1.00 | KDM2B (0.36) | KDM2BDPP4MEN1KMT2AALDH1A1 | |
| SCHEMBL19799022 | 1.00 | KDM2B (0.36) | KDM2BDPP4MEN1KMT2AALDH1A1 | |
| SCHEMBL21120723 | 1.00 | KDM2B (0.36) | KDM2BDPP4MEN1KMT2AALDH1A1 | |
| SCHEMBL19799041 | 0.95 | DPP4 (0.40) | KDM2BDPP4MEN1KMT2ASLC18A3 | |
| SCHEMBL19799055 | 0.95 | DPP4 (0.40) | KDM2BDPP4MEN1KMT2ASLC18A3 | |
| SCHEMBL21120719 | 0.95 | DPP4 (0.40) | KDM2BDPP4MEN1KMT2ASLC18A3 | |
| SCHEMBL19799043 | 0.95 | DPP4 (0.40) | KDM2BDPP4MEN1KMT2ASLC18A3 | |
| SCHEMBL19799049 | 0.95 | DPP4 (0.40) | KDM2BDPP4MEN1KMT2ASLC18A3 | |
| SCHEMBL26163646 | 0.93 | DPP4 (0.42) | KDM2BDPP4SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | KDM2B 3/4885DPP4 1273/4885MEN1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.